Clinical Trial Search

Primary: Mean Change From Baseline in Clinic Visit Trough Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24 Week…

Primary: Change From Baseline in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 24-week Treatment Period…

Primary: Ratio From Baseline of the Serum Cortisol Weighted Mean (0-24 Hours) on Day -1/1 (Baseline) and Day 42 — 0.99; 0.99; 0.96; 0.32 ratio from Baseline

Primary: Bleeding Frequency (Number of Total Bleeds) — 0; 54.5 Bleeds — p=<0.0001

Primary: Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Pseudoephedrine 30 mg Per 30 ml Syrup — 34.2 mm

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 12 — 77.18; 58.46; 63.33; -26.29 unit on a scale

Primary: Number of Patients With Adverse Events (AEs) — 103; 377; 8; 35 participants

Primary: PK Substudy - Area Under the Curve of Albendazole in Treatment in Day 1 — 1412.2; 1111 ng*h/mL

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores — 359; 396 Units on a scale*hours

Primary: The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo. — 141.8…

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores — 335; 359 Units on a scale*hours

Primary: PART I - Seizure Frequency — 7; 8.7; 7.1; 9.8 ln (Seizures) per 4 weeks

Primary: Seizure Frequency — 7.3; 5.7; 5.5 ln (Seizures) per 4 weeks

Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment — -54.0; -53.8 Percentage Change

Primary: Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores — 124; 146 Units on a scale*hours